Mitsides Nicos, Mitra Sandip, Cornelis Tom
Department of Renal Medicine, Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Center, Manchester; National Institute for Healthcare Research Devices for Dignity Healthcare Co-operative, Sheffield, UK.
Department of Nephrology, Jessa Hospital, Hasselt, Belgium.
Int J Nephrol Renovasc Dis. 2016 Jul 5;9:151-9. doi: 10.2147/IJNRD.S89411. eCollection 2016.
Despite technological advances in renal replacement therapy, the preservation of health and quality of life for individuals on dialysis still remains a challenge. The high morbidity and mortality in dialysis warrant further research and insight into the clinical domains of the technique and practice of this therapy. In the last 20 years, the focus of development in the field of hemodialysis (HD) has centered around adequate removal of urea and other associated toxins. High-dose HD offers an opportunity to improve mortality, morbidity, and quality of life of patients with end-stage kidney disease. However, the uptake of this modality is low, and the risk associated with the therapy is not fully understood. Recent studies have highlighted the evidence base and improved our understanding of this technique of dialysis. This article provides a review of high-dose and home HD, its clinical impact on patient outcome, and the controversies that exist.
尽管肾脏替代治疗技术取得了进步,但维持透析患者的健康和生活质量仍然是一项挑战。透析患者的高发病率和死亡率促使人们对该治疗技术和实践的临床领域进行进一步研究和深入了解。在过去20年中,血液透析(HD)领域的发展重点一直围绕充分清除尿素和其他相关毒素。高剂量血液透析为改善终末期肾病患者的死亡率、发病率和生活质量提供了契机。然而,这种治疗方式的采用率较低,且该治疗相关的风险尚未完全明确。最近的研究突出了证据基础,并增进了我们对这种透析技术的理解。本文对高剂量和家庭血液透析、其对患者预后的临床影响以及存在的争议进行了综述。